MiNK Matches Loss Estimates but Revenue Comes In at $200K vs $875K Expected
INKT sits 18% above its 52-week low of $8.48 on light trading volume (0.3× avg).
Summary
MiNK posted a Q3 adjusted loss of 50 cents a share, in line with the two-analyst consensus and narrower than the 65-cent loss a year ago. The problem is revenue: $200 thousand against an $875 thousand estimate, a wide miss for a company this small. Net loss for the quarter was $2.55 million. The stock is already down 20.2% this quarter and 10.2% year to date, and the last 10-Q carried a going-concern warning with reliance on dilutive ATM sales to fund operations — so the revenue shortfall matters more than the in-line EPS. The lone bright spot in the data is the sell side: both analysts rate it buy with a $44 median target, though estimates have not been revised in 30 days.
At the time of this announcement, INKT was trading at $10.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.1M. The 52-week trading range was $8.48 to $16.93. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.